Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX Stock Report

Market Cap: US$5.4b

Crinetics Pharmaceuticals Valuation

Is CRNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CRNX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CRNX's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRNX?

Other financial metrics that can be useful for relative valuation.

CRNX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3316.5x
Enterprise Value/EBITDA-16.6x
PEG Ration/a

Price to Book Ratio vs Peers

How does CRNX's PB Ratio compare to its peers?

The above table shows the PB ratio for CRNX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average10.5x
ABCM Abcam
6.1x39.3%US$5.5b
ALKS Alkermes
3.7x-7.0%US$4.9b
BPMC Blueprint Medicines
19.6x68.9%US$6.3b
RARE Ultragenyx Pharmaceutical
12.7x54.3%US$4.7b
CRNX Crinetics Pharmaceuticals
6.4x17.0%US$5.4b

Price-To-Book vs Peers: CRNX is good value based on its Price-To-Book Ratio (6.4x) compared to the peer average (10.5x).


Price to Earnings Ratio vs Industry

How does CRNX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a26.7%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a26.7%
n/an/an/a
No more companies

Price-To-Book vs Industry: CRNX is expensive based on its Price-To-Book Ratio (6.4x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is CRNX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRNX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CRNX's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRNX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$58.78
US$70.07
+19.2%
18.3%US$97.00US$48.00n/a14
Nov ’25US$56.69
US$70.07
+23.6%
18.3%US$97.00US$48.00n/a14
Oct ’25US$51.92
US$69.21
+33.3%
19.0%US$97.00US$48.00n/a14
Sep ’25US$53.06
US$69.21
+30.4%
19.0%US$97.00US$48.00n/a14
Aug ’25US$52.07
US$68.00
+30.6%
20.3%US$97.00US$48.00n/a14
Jul ’25US$46.07
US$67.50
+46.5%
21.4%US$97.00US$47.00n/a14
Jun ’25US$44.41
US$65.07
+46.5%
20.5%US$97.00US$47.00n/a14
May ’25US$45.05
US$56.86
+26.2%
16.7%US$80.00US$40.00n/a14
Apr ’25US$46.53
US$56.86
+22.2%
16.7%US$80.00US$40.00n/a14
Mar ’25US$46.03
US$51.23
+11.3%
16.3%US$65.00US$35.00n/a13
Feb ’25US$37.21
US$47.67
+28.1%
15.7%US$62.00US$35.00n/a12
Jan ’25US$35.58
US$47.27
+32.9%
17.5%US$62.00US$35.00n/a11
Dec ’24US$32.74
US$46.30
+41.4%
18.2%US$57.00US$33.00n/a10
Nov ’24US$29.55
US$47.89
+62.1%
17.5%US$60.00US$33.00US$56.699
Oct ’24US$29.74
US$48.11
+61.8%
17.6%US$60.00US$33.00US$51.929
Sep ’24US$17.44
US$43.22
+147.8%
18.9%US$57.00US$32.00US$53.069
Aug ’24US$19.45
US$47.13
+142.3%
16.6%US$57.00US$35.00US$52.078
Jul ’24US$18.02
US$47.13
+161.5%
16.6%US$57.00US$35.00US$46.078
Jun ’24US$21.85
US$45.78
+109.5%
18.2%US$57.00US$35.00US$44.419
May ’24US$20.50
US$45.56
+122.2%
18.5%US$57.00US$35.00US$45.059
Apr ’24US$16.06
US$44.38
+176.3%
17.7%US$57.00US$35.00US$46.538
Mar ’24US$19.64
US$41.50
+111.3%
16.3%US$55.00US$35.00US$46.036
Feb ’24US$20.00
US$43.17
+115.8%
17.0%US$55.00US$35.00US$37.216
Jan ’24US$18.30
US$43.50
+137.7%
17.6%US$55.00US$35.00US$35.586
Dec ’23US$17.57
US$43.50
+147.6%
17.6%US$55.00US$35.00US$32.746
Nov ’23US$18.50
US$42.67
+130.6%
15.4%US$52.00US$35.00US$29.556

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies